DK4073098T5 - Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse - Google Patents

Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK4073098T5
DK4073098T5 DK20830444.4T DK20830444T DK4073098T5 DK 4073098 T5 DK4073098 T5 DK 4073098T5 DK 20830444 T DK20830444 T DK 20830444T DK 4073098 T5 DK4073098 T5 DK 4073098T5
Authority
DK
Denmark
Prior art keywords
ultra
methods
long
fusion proteins
acting insulin
Prior art date
Application number
DK20830444.4T
Other languages
English (en)
Other versions
DK4073098T3 (da
Inventor
Thomas M Lancaster
Todd C Zion
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Application granted granted Critical
Publication of DK4073098T3 publication Critical patent/DK4073098T3/da
Publication of DK4073098T5 publication Critical patent/DK4073098T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
DK20830444.4T 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse DK4073098T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950803P 2019-12-19 2019-12-19
US202062988441P 2020-03-12 2020-03-12
PCT/US2020/063673 WO2021126584A1 (en) 2019-12-19 2020-12-07 Ultra-long acting insulin-fc fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
DK4073098T3 DK4073098T3 (da) 2023-11-20
DK4073098T5 true DK4073098T5 (da) 2024-07-22

Family

ID=74104207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20830444.4T DK4073098T5 (da) 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse

Country Status (17)

Country Link
US (3) US11352407B2 (da)
EP (2) EP4073098B1 (da)
JP (1) JP7405486B2 (da)
KR (2) KR20250142943A (da)
CN (1) CN114846025B (da)
AU (1) AU2020407365B2 (da)
BR (1) BR112022012071A2 (da)
CA (1) CA3159486A1 (da)
DK (1) DK4073098T5 (da)
FI (1) FI4073098T3 (da)
HR (1) HRP20231433T1 (da)
HU (1) HUE064376T2 (da)
IL (1) IL294051A (da)
LT (1) LT4073098T (da)
SI (1) SI4073098T1 (da)
WO (1) WO2021126584A1 (da)
ZA (1) ZA202206047B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICINAL LIGANDEN CONJUGATES, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREOF
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
SG10201907106VA (en) 2013-02-26 2019-09-27 Hanmi Pharmaceutical Co Ltd Novel insulin analog and use thereof
US9988617B2 (en) * 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
EP3250589A4 (en) 2015-01-29 2018-06-20 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
CN108026177B (zh) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
CN114835795A (zh) 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
CN110267674A (zh) 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
US20200181258A1 (en) 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TW201835099A (zh) 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
AU2019255611A1 (en) 2018-04-16 2020-11-12 University Of Utah Research Foundation Glucose-responsive insulin
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
AU2019349934B2 (en) 2018-09-25 2024-12-05 Absci Corporation Protein purification methods
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
JP2022507627A (ja) 2018-11-19 2022-01-18 ケース ウェスタン リザーブ ユニバーシティ ポリ-アラニンc-ドメインのサブセグメントを有する単鎖インスリンアナログ
WO2020236762A2 (en) 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
TW202342552A (zh) 2022-03-16 2023-11-01 大陸商北京拓界生物醫藥科技有限公司 人胰島素類似物、其融合蛋白及醫藥用途

Also Published As

Publication number Publication date
EP4282473A3 (en) 2024-02-21
IL294051A (en) 2022-08-01
AU2020407365A1 (en) 2022-06-09
US11555058B2 (en) 2023-01-17
US20220064251A1 (en) 2022-03-03
LT4073098T (lt) 2023-12-11
CA3159486A1 (en) 2021-06-24
HUE064376T2 (hu) 2024-03-28
EP4073098B1 (en) 2023-09-27
KR20220115975A (ko) 2022-08-19
EP4282473A2 (en) 2023-11-29
AU2020407365B2 (en) 2023-09-21
EP4073098A1 (en) 2022-10-19
HRP20231433T1 (hr) 2024-03-29
DK4073098T3 (da) 2023-11-20
KR20250142943A (ko) 2025-09-30
BR112022012071A2 (pt) 2022-08-30
SI4073098T1 (sl) 2023-12-29
WO2021126584A1 (en) 2021-06-24
NZ788617A (en) 2024-10-25
JP7405486B2 (ja) 2023-12-26
US11352407B2 (en) 2022-06-07
FI4073098T3 (fi) 2023-11-15
CN114846025B (zh) 2025-11-11
CN114846025A (zh) 2022-08-02
JP2023507376A (ja) 2023-02-22
US20210309709A1 (en) 2021-10-07
US12606605B2 (en) 2026-04-21
US20230250148A1 (en) 2023-08-10
ZA202206047B (en) 2023-08-30
KR102865175B1 (ko) 2025-09-30

Similar Documents

Publication Publication Date Title
DK4186920T3 (da) Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
DK4232463T3 (da) Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses
IL288373A (en) flt3l-fc fusion proteins and methods of use
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL281683A (en) Dll3 binding proteins and methods of use
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL292877A (en) Angiotensinogen (agt) irna compositions and methods of use thereof
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
IL287650A (en) Engineered chimeric fusion protein compositions and methods of use thereof
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
DK3660045T3 (da) Polypeptid, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
IL275742A (en) IL-22 FC fusion proteins and methods of use
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
IL281641A (en) Methods and uses of variant cd80 fusion proteins and related constructs
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3743447T3 (da) B7-H4-antistoffer og fremgangsmåder til anvendelse deraf